Essential Steps to Successful BioPharma Partnering
What's Hot & What's Not in Antibody Drug Conjugates Licensing
In this webinar, learn what targets are suitable, what are the trends in linkers and the drugs to be attached to the antibodies, how are companies dealing with the complexities of internalization and high cost of goods, what kind of data will drive an ADC licensing deal, how do the ADCs fit in the world of immuno-oncology and what is the future for ADCs.
Pullan’s Pieces II – A Business Development View of the Central Nervous System Landscape
Precision Medicine in Central Nervous System Drug Development
This webinar discusses lessons we can learn from the use of precision medicine in oncology, how has a recent clinical precision medicine application shown potential in the treatment of Alzheimer’s, what questions should you ask before you add a new biomarker to your clinical trial, the pros and cons of using biomarkers as surrogate endpoints.
From Founding to Exit: A Life Science Business Founder Perspective
Bispecifics in Oncology and Immuno Oncology
This webinar roundtable explores interesting technologies, the scientific issues, the clinical opportunities for developing multivalent biologics platforms, whether certain technologies, such as antibodies, their fragments, or non-antibody scaffolds, are superior to others, the pros and cons of such bispecifics for improving management of patients, and licensing and commercial strategies.
Understanding Representations and Warranties Insurance in M&A
Best Practices for Fundraising and M&A Due Diligence
This webinar explores the importance of establishing early goals and objectives for the process, how to get the right people to ask the right questions in advance of the process, how to build credibility by defining goals and demonstrating they can be achieved, much more.
Negotiating Working Capital: Maximizing M&A Valuation
This webinar provides information on how working-capital hurdles provide protection and benefits to both parties in a transaction, how working-capital hurdles are calculated, and how purchase price adjustments are made based on agreed upon working capital hurdles.
The Nuts & Bolts of Due Diligence in Biopharma Partnering
Bridging Valuation Gaps with Creative Deal Structures
The Good, The Bad and The Ugly of IP Monetization